C-Reactive Protein Concentration in Steady-State Bronchiectasis: Prognostic Value of Future Severe Exacerbations. Data From the Spanish Registry of Bronchiectasis (RIBRON).
Bronchiectasis
Bronquiectasias
C-reactive protein
Exacerbación
Exacerbation
Hospitalización
Hospitalization
Proteína C reactiva
Pseudomonas aeruginosa
Journal
Archivos de bronconeumologia
ISSN: 2173-5751
Titre abrégé: Arch Bronconeumol (Engl Ed)
Pays: Spain
ID NLM: 101777538
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
09
09
2019
revised:
11
12
2019
accepted:
15
12
2019
pubmed:
26
4
2020
medline:
25
6
2021
entrez:
26
4
2020
Statut:
ppublish
Résumé
Both systemic inflammation and exacerbations have been associated with greater severity of bronchiectasis. Our objective was to analyze the prognostic value of the peripheral concentration of C-reactive protein (CRP) for the number and severity of exacerbations in patients with bronchiectasis. Patients from the Spanish Bronchiectasis Registry (RIBRON) with valid data on their CRP value (in a clinically stable phase) and valid data on exacerbations during the first year of follow-up were included. A logistic regression analysis was used to evaluate the prognostic value of the CRP concentration (divided into tertiles) with the presence of at least one severe exacerbation or at least two mild-moderate exacerbations during the first year of follow-up. 802 patients (mean age: 68.1 [11.1 years], 65% female) were included. Of these, 33.8% and 13%, respectively, presented ≥2 mild-moderate exacerbations or at least one severe exacerbation during the first year of follow-up. The mean value of the CRP was 6.5 (17.6mg/L). Patients with a CRP value between 0.4 and 2.7mg/L (second tertile) and ≥2.7mg/L (third tertile) presented a 2.9 (95%CI: 1.4-5.9) and 4.2 (95%CI: 2.2-8.2) times greater probability, respectively, of experiencing a severe exacerbation than those with <0.4mg/L (control group), regardless of bronchiectasis severity or a history of previous exacerbations. However, the CRP value did not present any prognostic value for the number of mild-moderate exacerbations. The CRP value was associated with a greater risk of future severe exacerbations but not with mild or moderate exacerbations in patients with steady-state bronchiectasis.
Sections du résumé
BACKGROUND
Both systemic inflammation and exacerbations have been associated with greater severity of bronchiectasis. Our objective was to analyze the prognostic value of the peripheral concentration of C-reactive protein (CRP) for the number and severity of exacerbations in patients with bronchiectasis.
METHODS
Patients from the Spanish Bronchiectasis Registry (RIBRON) with valid data on their CRP value (in a clinically stable phase) and valid data on exacerbations during the first year of follow-up were included. A logistic regression analysis was used to evaluate the prognostic value of the CRP concentration (divided into tertiles) with the presence of at least one severe exacerbation or at least two mild-moderate exacerbations during the first year of follow-up.
RESULTS
802 patients (mean age: 68.1 [11.1 years], 65% female) were included. Of these, 33.8% and 13%, respectively, presented ≥2 mild-moderate exacerbations or at least one severe exacerbation during the first year of follow-up. The mean value of the CRP was 6.5 (17.6mg/L). Patients with a CRP value between 0.4 and 2.7mg/L (second tertile) and ≥2.7mg/L (third tertile) presented a 2.9 (95%CI: 1.4-5.9) and 4.2 (95%CI: 2.2-8.2) times greater probability, respectively, of experiencing a severe exacerbation than those with <0.4mg/L (control group), regardless of bronchiectasis severity or a history of previous exacerbations. However, the CRP value did not present any prognostic value for the number of mild-moderate exacerbations.
CONCLUSIONS
The CRP value was associated with a greater risk of future severe exacerbations but not with mild or moderate exacerbations in patients with steady-state bronchiectasis.
Identifiants
pubmed: 32331706
pii: S0300-2896(19)30625-8
doi: 10.1016/j.arbres.2019.12.017
pii:
doi:
Substances chimiques
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
spa
Sous-ensembles de citation
IM
Pagination
21-27Investigateurs
Annie Navarro Rolon
(AN)
Patricia Minguez
(P)
Rosanel Amaro
(R)
Angela Cervera
(A)
Marina Blanco
(M)
Ainhoa Gomez
(A)
Eleuterio Llorca
(E)
Alicia Padilla
(A)
Edmundo Rosales
(E)
Laura Carrasco
(L)
Marcelo Razquin
(M)
Informations de copyright
Copyright © 2020. Publicado por Elsevier España, S.L.U.
Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388
pubmed: 32275452
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
J Med Virol. 2020 Oct;92(10):1915-1921
pubmed: 32293753
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Crit Care. 2020 Mar 18;24(1):108
pubmed: 32188484
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
J Korean Med Sci. 2020 Apr 06;35(13):e142
pubmed: 32242348
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Allergy Clin Immunol. 2020 Jul;146(1):110-118
pubmed: 32294485
Nicotine Tob Res. 2020 Aug 24;22(9):1650-1652
pubmed: 32242236
Arch Acad Emerg Med. 2020 Mar 24;8(1):e35
pubmed: 32232218
J Clin Med. 2020 Mar 20;9(3):
pubmed: 32244852
N Engl J Med. 2020 Jun 11;382(24):2372-2374
pubmed: 32302078
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386
pubmed: 32240123
Clin Infect Dis. 2020 Nov 19;71(16):2089-2098
pubmed: 32361738
Emerg Infect Dis. 2016 Jan;22(1):49-55
pubmed: 26692185
Chin Med J (Engl). 2020 May 5;133(9):1032-1038
pubmed: 32118640
BMJ. 2020 Mar 26;368:m1091
pubmed: 32217556
Eur Respir J. 2020 May 14;55(5):
pubmed: 32269089
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Clin Infect Dis. 2020 Sep 12;71(6):1393-1399
pubmed: 32271369
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Mil Med Res. 2020 Feb 6;7(1):4
pubmed: 32029004
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Clin Infect Dis. 2020 Mar 16;:
pubmed: 32173725
J Infect. 2020 Jun;80(6):e14-e18
pubmed: 32171866
Tob Induc Dis. 2020 Mar 20;18:20
pubmed: 32206052
J Med Virol. 2020 Jul;92(7):797-806
pubmed: 32198776
Nicotine Tob Res. 2020 Aug 24;22(9):1653-1656
pubmed: 32399563
Eur J Intern Med. 2020 May;75:107-108
pubmed: 32192856
Int J Infect Dis. 2020 Jun;95:421-428
pubmed: 32289565